<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4892">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01195090</url>
  </required_header>
  <id_info>
    <org_study_id>09MMHIS047</org_study_id>
    <nct_id>NCT01195090</nct_id>
  </id_info>
  <brief_title>Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea</brief_title>
  <acronym>JAS</acronym>
  <official_title>Efficacy of Adding Sitagliptin or Pioglitazone to Patients With Type 2 Diabetes Insufficiently Controlled With Metformin and Sulfonylurea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sung-Chen Liu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mackay Memorial Hospital</source>
  <oversight_info>
    <authority>Taiwan: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 24-weeks study will to compare the glycemic efficacy and safety of sitagliptin with
      pioglitazone in patients with type 2 diabetes who had inadequate glycemic control despite
      dual therapy with metformin and a sulfonylurea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, randomized, parallel, 24-week study. Inclusion criteria:
      type 2 diabetes patients who were treated with stable doses of sulfonylurea and metformin to
      their half maximally dose (sulfonylureas &gt; half maximal dose, and metformin &gt; 1500 mg/d) for
      &gt; 10 weeks. &gt; 20 years old; A1C:&gt; 7.0 % and &lt; 11% Exclusion criteria: insulin use within 12
      weeks of the screening visit, any contraindications for use of sitagliptin or pioglitazone,
      impaired renal function (serum creatinine &gt; 1.4 mg/dl), alanine aminotransferase (ALT) or
      aspartate aminotransferase levels (AST) &gt; 2.5 times the upper limit of normal (ULN), current
      or prepare to pregnancy and lactation.

      Primary Purpose:

      compare the change in hemoglobin A1c and the proportion of patients achieving A1C &lt; 7%
      between the 2 groups

      Secondary Purposes:

        1. Changes in fasting plasma glucose, high sensitive C-reactive protein (hsCRP)

        2. Homeostasis model assessment-β cell function(HOMA-β) will be calculated to assess
           changes in β-cell function and HOMA-insulin resistance(HOMA-IR)to assess changes in
           insulin resistance

        3. Body weight change, proportion of side effects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Change in Glycosylated Hemoglobin (A1C)</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A1C change from baseline to 24 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline A1C</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>baseline A1C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentages of Patient Achieving an A1C &lt;7%</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentages of patient achieving an A1C &lt;7% at endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Fasting Plasma Glucose</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>fasting serum sugar change from baseline to 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in High Sensitive C-reactive Protein</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>fasting high sensitive serum C-reactive protein change from baseline to 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Homoeostasis Model Assessment of Insulin Resistance (HOMA-IR)</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>HOMA-IR change from baseline to 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight Change</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>body weight change from baseline to 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Patients With Total Adverse Events (AE)</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>percentages of total adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Total-cholesterol</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total-cholesterol change from baseline to 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Low-density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>LDL-C change from baseline to 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Triglycerides(TG)</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>TG change from baseline to 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting High-density Lipoprotein Cholesterol(HDL-C)</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>HDL-C change from baseline to 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Alanine-aminotransferase (ALT)</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ALT change from baseline to 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Patients With Mild to Moderate Hypoglycemia</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of mild to moderate hypoglycemia after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Patients With Edema</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>proportion of edema after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Patients With Gastrointestinal Adverse Events</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Proportion of Gastrointestinal adverse events after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Patients With Nasopharyngitis</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Proportion of Nasopharyngitis after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Patients With Severe Hypoglycemia</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Proportion of severe hypoglycemia after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Fasting Plasma Glucose</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline fasting plasma glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline High Sensitive C-reactive Protein</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline high sensitive C-reactive Protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Homoeostasis Model Assessment of Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Baseline HOMA-IR</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline HOMA-IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Alanine-aminotransferase (ALT)</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Baseline alanine-aminotransferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Body Weight</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Baseline body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Total Cholesterol</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline Total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Triglyceride (TG)</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline TG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Low-density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline High-density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline HDL-C</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>add sitagliptin100mg/d to pre-study OADs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>add pioglitazone 30mg/d to pre-study OADs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>add sitagliptin100mg/d to pre-study OADs</description>
    <arm_group_label>sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>add pioglitazone 30mg/d to pre-study OADs</description>
    <arm_group_label>pioglitazone</arm_group_label>
    <other_name>actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes patients who were treated with stable doses of sulfonylurea and
             metformin to their half maximally dose (sulfonylureas &gt; half maximal dose, and
             metformin &gt; 1500 mg/d) for &gt; 10 weeks

          -  &gt; 20 years old

          -  A1C: &gt; 7.0 % and &lt; 11%

        Exclusion Criteria:

          -  Insulin use within 12 weeks of the screening visit

          -  Any contraindications for use of sitagliptin or pioglitazone, impaired renal function
             (serum creatinine &gt; 1.4 mg/dl), alanine aminotransferase or aspartate
             aminotransferase levels &gt; 2.5 times the upper limit of normal

          -  Current or prepare to pregnancy and lactation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-Chen Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 9, 2012</lastchanged_date>
  <firstreceived_date>September 2, 2010</firstreceived_date>
  <firstreceived_results_date>April 18, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mackay Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Sung-Chen Liu</investigator_full_name>
    <investigator_title>Mackay Memorial Hospital</investigator_title>
  </responsible_party>
  <keyword>sitagliptin</keyword>
  <keyword>pioglitazone</keyword>
  <keyword>type 2 diabetes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Sitagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was started from 01 OCT 2009 to 27 SEP 2011</recruitment_details>
      <pre_assignment_details>we screened 135 patients and 120 patients were randomized in a 1: 1 ratio to one of the treatment groups.
reson for excluded: 4 patients: ALT or AST &gt;2.5x ULN 8 patiens : withdraw informed consent 3 patiens: baseline A1C&gt;11%</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin</title>
          <description>add sitagliptin100mg/d to pre-study OADs</description>
        </group>
        <group group_id="P2">
          <title>Pioglitazone</title>
          <description>add pioglitazone 30mg/d to pre-study OADs</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin</title>
          <description>add sitagliptin100mg/d to pre-study OADs</description>
        </group>
        <group group_id="B2">
          <title>Pioglitazone</title>
          <description>add pioglitazone 30mg/d to pre-study OADs</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="60"/>
                <measurement group_id="B3" value="120"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
                <measurement group_id="B2" value="49"/>
                <measurement group_id="B3" value="91"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60.1" spread="8.9"/>
                <measurement group_id="B2" value="58.1" spread="8.3"/>
                <measurement group_id="B3" value="59.1" spread="8.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="38"/>
                <measurement group_id="B2" value="37"/>
                <measurement group_id="B3" value="75"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="45"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Taiwan</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="60"/>
                <measurement group_id="B3" value="120"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Glycosylated Hemoglobin (A1C)</title>
        <description>A1C change from baseline to 24 weeks</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>An intent-to-treat analysis with last observation carried forward was used to assess efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change in Glycosylated Hemoglobin (A1C)</title>
            <description>A1C change from baseline to 24 weeks</description>
            <units>percentage of Hb</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.71" spread="0.12"/>
                  <measurement group_id="O2" value="-0.94" spread="0.12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The change from baseline in A1C were determined using an analysis of co-variance (ANCOVA) model with the factor ‘treatment’ and baseline A1C as covariate.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.165</p_value>
            <p_value_desc>The change from baseline in A1C were determined using an analysis of co-variance (ANCOVA) model with the factor ‘treatment’ and baseline A1C as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Fasting Plasma Glucose</title>
        <description>fasting serum sugar change from baseline to 24 weeks</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>An intent-to-treat (ITT) analysis with last observation carried forward was used to assess efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in Fasting Plasma Glucose</title>
            <description>fasting serum sugar change from baseline to 24 weeks</description>
            <units>mg/dl</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-23" spread="4.0"/>
                  <measurement group_id="O2" value="-36" spread="4.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in High Sensitive C-reactive Protein</title>
        <description>fasting high sensitive serum C-reactive protein change from baseline to 24 weeks</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>An intent-to-treat analysis with last observation carried forward was used to assess efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in High Sensitive C-reactive Protein</title>
            <description>fasting high sensitive serum C-reactive protein change from baseline to 24 weeks</description>
            <units>mg/dl</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.07" spread="0.04"/>
                  <measurement group_id="O2" value="-0.19" spread="0.04"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Homoeostasis Model Assessment of Insulin Resistance (HOMA-IR)</title>
        <description>HOMA-IR change from baseline to 24 weeks</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>An intent-to-treat analysis with last observation carried forward was used to assess efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in Homoeostasis Model Assessment of Insulin Resistance (HOMA-IR)</title>
            <description>HOMA-IR change from baseline to 24 weeks</description>
            <units>HOMA-IR score</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.00" spread="0.35"/>
                  <measurement group_id="O2" value="-1.56" spread="0.35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight Change</title>
        <description>body weight change from baseline to 24 weeks</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>An intent-to-treat analysis with last observation carried forward was used to assess efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Body Weight Change</title>
            <description>body weight change from baseline to 24 weeks</description>
            <units>kg</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.26" spread="0.32"/>
                  <measurement group_id="O2" value="1.34" spread="0.32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Patients With Total Adverse Events (AE)</title>
        <description>percentages of total adverse events</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All patients who had taken at least one dose of study medication were included in the safety analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Patients With Total Adverse Events (AE)</title>
            <description>percentages of total adverse events</description>
            <units>percentage</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43.1"/>
                  <measurement group_id="O2" value="51.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Total-cholesterol</title>
        <description>Total-cholesterol change from baseline to 24 weeks</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>An intent-to-treat analysis with last observation carried forward was used to assess efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Fasting Total-cholesterol</title>
            <description>Total-cholesterol change from baseline to 24 weeks</description>
            <units>mg/dl</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.6" spread="3.9"/>
                  <measurement group_id="O2" value="9.9" spread="4.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Low-density Lipoprotein Cholesterol (LDL-C)</title>
        <description>LDL-C change from baseline to 24 weeks</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>An intent-to-treat analysis with last observation carried forward was used to assess efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Fasting Low-density Lipoprotein Cholesterol (LDL-C)</title>
            <description>LDL-C change from baseline to 24 weeks</description>
            <units>mg/dl</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.2" spread="3.7"/>
                  <measurement group_id="O2" value="6.6" spread="3.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Triglycerides(TG)</title>
        <description>TG change from baseline to 24 weeks</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>An intent-to-treat analysis with last observation carried forward was used to assess efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Fasting Triglycerides(TG)</title>
            <description>TG change from baseline to 24 weeks</description>
            <units>mg/dl</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.3" spread="9.3"/>
                  <measurement group_id="O2" value="-23.9" spread="9.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting High-density Lipoprotein Cholesterol(HDL-C)</title>
        <description>HDL-C change from baseline to 24 weeks</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>An intent-to-treat analysis with last observation carried forward was used to assess efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Fasting High-density Lipoprotein Cholesterol(HDL-C)</title>
            <description>HDL-C change from baseline to 24 weeks</description>
            <units>mg/dl</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.3" spread="1.2"/>
                  <measurement group_id="O2" value="6.3" spread="1.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Alanine-aminotransferase (ALT)</title>
        <description>ALT change from baseline to 24 weeks</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>An intent-to-treat analysis with last observation carried forward was used to assess efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Fasting Plasma Alanine-aminotransferase (ALT)</title>
            <description>ALT change from baseline to 24 weeks</description>
            <units>IU/L</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.0" spread="2.4"/>
                  <measurement group_id="O2" value="-4.5" spread="2.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Patients With Mild to Moderate Hypoglycemia</title>
        <description>Incidence of mild to moderate hypoglycemia after treatment</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All patients who had taken at least one dose of study medication were included in the safety analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Patients With Mild to Moderate Hypoglycemia</title>
            <description>Incidence of mild to moderate hypoglycemia after treatment</description>
            <units>percentage</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="8.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Patients With Edema</title>
        <description>proportion of edema after treatment</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All patients who had taken at least one dose of study medication were included in the safety analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Patients With Edema</title>
            <description>proportion of edema after treatment</description>
            <units>percentage</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="27.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Patients With Gastrointestinal Adverse Events</title>
        <description>Proportion of Gastrointestinal adverse events after treatment</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All patients who had taken at least one dose of study medication were included in the safety analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Patients With Gastrointestinal Adverse Events</title>
            <description>Proportion of Gastrointestinal adverse events after treatment</description>
            <units>percentge</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20.0"/>
                  <measurement group_id="O2" value="6.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Patients With Nasopharyngitis</title>
        <description>Proportion of Nasopharyngitis after treatment</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All patients who had taken at least one dose of study medication were included in the safety analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Patients With Nasopharyngitis</title>
            <description>Proportion of Nasopharyngitis after treatment</description>
            <units>percentage</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20.0"/>
                  <measurement group_id="O2" value="18.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline A1C</title>
        <description>baseline A1C</description>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <population>baseline Laboratory measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Baseline A1C</title>
            <description>baseline A1C</description>
            <units>percentage of Hb</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8.27" spread="0.86"/>
                  <measurement group_id="O2" value="8.54" spread="0.97"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentages of Patient Achieving an A1C &lt;7%</title>
        <description>The percentages of patient achieving an A1C &lt;7% at endpoint</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>The percentages of patient achieving an A1C &lt;7% at endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Percentages of Patient Achieving an A1C &lt;7%</title>
            <description>The percentages of patient achieving an A1C &lt;7% at endpoint</description>
            <units>percentage</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28.3"/>
                  <measurement group_id="O2" value="28.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chi-square test for percentages of patient achieving an A1C &lt;7%</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Chi-square test</non_inferiority_desc>
            <p_value>0.954</p_value>
            <p_value_desc>Chi-square test</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Chi-Square</param_type>
            <param_value>0.0034</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Patients With Severe Hypoglycemia</title>
        <description>Proportion of severe hypoglycemia after treatment</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Proportion of severe ypoglycemia after treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Patients With Severe Hypoglycemia</title>
            <description>Proportion of severe hypoglycemia after treatment</description>
            <units>percentage</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Fasting Plasma Glucose</title>
        <description>Baseline fasting plasma glucose</description>
        <time_frame>baseline</time_frame>
        <safety_issue>No</safety_issue>
        <population>Baseline fasting plasma glucose</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Baseline Fasting Plasma Glucose</title>
            <description>Baseline fasting plasma glucose</description>
            <units>mg/dl</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="177" spread="47"/>
                  <measurement group_id="O2" value="182" spread="38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline High Sensitive C-reactive Protein</title>
        <description>Baseline high sensitive C-reactive Protein</description>
        <time_frame>baseline</time_frame>
        <safety_issue>No</safety_issue>
        <population>Baseline high sensitive C-reactive Protein</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Baseline High Sensitive C-reactive Protein</title>
            <description>Baseline high sensitive C-reactive Protein</description>
            <units>mg/dl</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.38" spread="0.36"/>
                  <measurement group_id="O2" value="0.42" spread="0.68"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Homoeostasis Model Assessment of Insulin Resistance (HOMA-IR)</title>
        <description>Baseline HOMA-IR</description>
        <time_frame>Baseline HOMA-IR</time_frame>
        <safety_issue>No</safety_issue>
        <population>Baseline HOMA-IR</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Baseline Homoeostasis Model Assessment of Insulin Resistance (HOMA-IR)</title>
            <description>Baseline HOMA-IR</description>
            <units>HOMA-IR score</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5.6" spread="3.8"/>
                  <measurement group_id="O2" value="4.8" spread="3.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Alanine-aminotransferase (ALT)</title>
        <description>Baseline alanine-aminotransferase</description>
        <time_frame>Baseline</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Baseline alanine-aminotransferase</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Baseline Alanine-aminotransferase (ALT)</title>
            <description>Baseline alanine-aminotransferase</description>
            <units>IU/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34.2" spread="17.5"/>
                  <measurement group_id="O2" value="28.5" spread="15.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Body Weight</title>
        <description>Baseline body weight</description>
        <time_frame>Baseline</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Baseline body weight</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Baseline Body Weight</title>
            <description>Baseline body weight</description>
            <units>kg</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="69.4" spread="13.6"/>
                  <measurement group_id="O2" value="65.4" spread="10.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Total Cholesterol</title>
        <description>Baseline Total cholesterol</description>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <population>Baseline Total cholesterol</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Baseline Total Cholesterol</title>
            <description>Baseline Total cholesterol</description>
            <units>mg/dl</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="174" spread="31"/>
                  <measurement group_id="O2" value="194" spread="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Triglyceride (TG)</title>
        <description>Baseline TG</description>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <population>Baseline TG</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Baseline Triglyceride (TG)</title>
            <description>Baseline TG</description>
            <units>mg/dl</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="137" spread="74"/>
                  <measurement group_id="O2" value="164" spread="73"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Low-density Lipoprotein Cholesterol (LDL-C)</title>
        <description>Baseline LDL-C</description>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <population>Baseline LDL-C</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Baseline Low-density Lipoprotein Cholesterol (LDL-C)</title>
            <description>Baseline LDL-C</description>
            <units>mg/dl</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="102" spread="25"/>
                  <measurement group_id="O2" value="111" spread="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline High-density Lipoprotein Cholesterol (HDL-C)</title>
        <description>Baseline HDL-C</description>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <population>Baseline HDL-C</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>add sitagliptin100mg/d to pre-study OADs</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>add pioglitazone 30mg/d to pre-study OADs</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Baseline High-density Lipoprotein Cholesterol (HDL-C)</title>
            <description>Baseline HDL-C</description>
            <units>mg/dl</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="42" spread="12"/>
                  <measurement group_id="O2" value="43" spread="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>adverse event was recorded after 12 weeks and 24 weeks treatment or was recorded if adverse event was noted at any time during the study period.</time_frame>
      <desc>All adverse events was recorded after treatment. Symptomatic hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia and severe hypoglycemia was defined as an event with symptoms consistent with hypoglycemia in which the patient required the assistance of another person.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin</title>
          <description>add sitagliptin100mg/d to pre-study OADs</description>
        </group>
        <group group_id="E2">
          <title>Pioglitazone</title>
          <description>add pioglitazone 30mg/d to pre-study OADs</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal adverse event</sub_title>
                <description>Gastrointestinal adverse event was recorded at any visit after treatment</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>edema</sub_title>
                <description>12 patients in the pioglitazone group had peripheral edema after treamtnet for 12 weeks and 16 patients had edema after treatment for 24 weeks.
No edema in the sitagliptin group was noted.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Hypoglycemic events occurred in 5 patients in the pioglitazone group and in 6 patients in the sitagliptin group. All the adverse events were mild to moderate.</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Nasopharyngitis was recorded at every visit</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="60"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The reasons for withdrawal:
lost to follow-up:2 in pioglitazone and 2 in sitagliptin protocol violation:4 in pioglitazone and 3 in sitagliptin edema:1 in pioglitazone, ALT &gt;3 times ULN:1 in pioglitazone gastrointestinal events:1 in sitagliptin</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Sung-Chen Liu</name_or_title>
      <organization>Department of Internal Medicine, Mackay Memorial Hospital</organization>
      <phone>886-2-2543-3535 ext 2174</phone>
      <email>pine3.tw@yahoo.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
